RxDoctor Payments Data

Mark Bromberg

Neurology · Salt Lake City, UTNPI 1164517009

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Argenx US, Inc. at 52.7% of the total. 2025 is the largest year on record at $80,278, 3.8 times the $21,038 reported in 2019. Among neurology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$265,286in general payments, 2019–2025

Across 183 payments — averaging $1449.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$140K
  • Grifols USA, LLC$78K
  • Takeda Pharmaceuticals U.S.A., Inc.$17K
  • Tanabe Pharma America, Inc.$13K
  • AstraZeneca$11K
  • Shire North American Group Inc$7K
  • plus $424 from 4 others
$666,681in research payments, 2019–2025

Across 59 payments — averaging $11,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$323K
  • Sanofi$160K
  • Orion Corporation$115K
  • UCB Biosciences Inc.$43K
  • AstraZeneca$18K
  • Argenx US, Inc.$7K

What the payments were for

  • Consulting fees$147,55456%
  • Speaking & faculty fees$95,72536%
  • Travel & lodging$17,1336%
  • Food & beverage$4,8662%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$265,286 in reported general payments places this provider in the 95th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Medicare billing

Part B allowed, 2024
$33,132
Medicare patients
144
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone45$581,297
GammakedImmune Globul G/Gly/Iga Avg 4615$227,893
Riluzole48$11,086
Mycophenolate Mofetil41$7,514
Gabapentin78$2,849
Carbidopa-LevodopaCarbidopa/Levodopa26$1,541
Baclofen19$1,487
Primidone18$794
Atropine Sulfate12$687
Prednisone53$553
Amitriptyline Hcl20$307
Azathioprine17$258
Pregabalin18$240
Oxybutynin Chloride11$208
Tramadol Hcl11$176

Paid to pharmacies, not to this prescriber.

Other neurology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →